ArticleScientific reports2017
The PPE2 protein of Mycobacterium tuberculosis translocates to host nucleus and inhibits nitric oxide production.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- Article
- Article
- Integrative multi-omics analysis identifies SELL and PRF1 as key immune biomarkers and therapeutic targets in tuberculosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Epigenetic Reprogramming byAntibiotics (Basel, Switzerland) · 2026Review
- The arginase-polyamine signaling axis in immune cells: Implications for immune modulation and host-pathogen interactions.iScience · 2026Review
- TZ1391: a computationally designed circular mRNA multi-epitope vaccine candidate against Mycobacterium tuberculosis via TLR3 immunomodulation.BMC immunology · 2026Article
- Cobamide metabolism, regulation, and adaptation inJournal of bacteriology · 2025Review
- Article
- Characterization of PPE19 as a novel mediator ofmSphere · 2025Article
- The PE/PPE family proteins ofFrontiers in immunology · 2025Review
- Article
- Nitric Oxide Therapeutics: New Hopes for More Effective Tuberculosis Treatment Combine with Targeted and Controlled Nanotechnology.International journal of nanomedicine · 2025Review
- The SH3-binding domain of chorismate mutase protein ofiScience · 2024Article
- Discovering peptides and computational investigations of a multiepitope vaccine targetSynthetic and systems biotechnology · 2024Article
- A novel regulatory interplay between atypical B12 riboswitches and uORF translation in Mycobacterium tuberculosis.Nucleic acids research · 2024Article
- Live Attenuated Vaccines against Tuberculosis: Targeting the Disruption of Genes Encoding the Secretory Proteins of Mycobacteria.Vaccines · 2024Review
- Article
- A mycobacterial effector promotes ferroptosis-dependent pathogenicity and dissemination.Nature communications · 2023Article
- Immunological effects of the PE/PPE family proteins ofFrontiers in immunology · 2023Review
- Role of MHC class I pathways inFrontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium tuberculosis, the bacterium that causes tuberculosis, is one of the most successful pathogens of humans. It has evolved several adaptive skills and evasion mechanisms to hijack the immunologically educated host to suit its intracellular lifestyle. Here, we show that one of the unique PPE family member proteins of M. tuberculosis, PPE2, can limit nitric oxide (NO) production by inhibiting inos gene transcription. PPE2 protein has a leucine zipper DNA-binding motif and a functional nuclear localization signal. PPE2 was translocated into the macrophage nucleus via the classical importin α/β pathway where it interacted with a GATA-binding site overlapping with the TATA box of inos promoter and inhibited NO production. PPE2 prolonged intracellular survival of a surrogate bacterium M. smegmatis in vitro as well as in vivo. This information are likely to improve our knowledge of host-pathogen interactions during M. tuberculosis infection which is crucial for designing effective anti-TB therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.